Get started
Author

Claire Ribet

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
2018 · Michelle Rosenzwajg, Roberta Lorenzon, et al. · Annals of the Rheumatic Diseases · 415
PDF
The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial
2024 · Roberta Lorenzon, Claire Ribet, et al. · Journal of Autoimmunity · 50
Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol
2018 · Roberta Lorenzon, Encarnita Mariotti-Ferrandiz, et al. · BMJ Open · 45
PDF
Studies on the Potential of Microparticles EnTropping pDNA-Poly (Aminoacids) Complexes as Vaccine Delivery Systems
2001 · Marie-Ange Benoit, Claire Ribet, et al. · Journal of drug targeting · 25
Clinical correlates of lifetime and current comorbidity patterns in autoimmune and inflammatory diseases
2024 · Signe Hässler, Roberta Lorenzon, et al. · Journal of Autoimmunity · 17
IL-1β signaling modulates T follicular helper and regulatory cells in human lymphoid tissues
2025 · Romain Vaineau, Raphaël Jeger-Madiot, et al. · JCI Insight · 11
Immunologic Profiling Suggests an Association Between Treg Cell Dysfunction and Pain in Knee Osteoarthritis
2025 · Marie Binvignat, Johanna Dubois, et al. · Arthritis & Rheumatology · 8
PDF
Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19
2022 · Joe-Elie Salem, Nadjib Hammoudi, et al. · Archives of cardiovascular diseases · 3
PDF
Clinical data specification and coding for cross-analyses with omics data in autoimmune disease trials
2018 · Lorenzon Roberta, Drakos Iannis, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 3
PDF
Efficacy and safety of low-dose IL-2 in people with newly diagnosed type 1 diabetes (DIABIL-2): a double-blind, multicentre, randomised, placebo-controlled, phase 2b trial
2026 · Michelle Rosenzwajg, Agnès Hartemann, et al. · The Lancet Diabetes & Endocrinology · 1
Low-dose interleukin-2 for recurrent early pregnancy loss: A proof-of-concept study
2026 · Arsene Mekinian, Noémie Abisror, et al. · La Revue de Médecine Interne · 1
PDF
A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease
2026 · Marie Binvignat, Federica Martina, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study
2025 · David Klatzmann, Arsene Mekinian, et al. · Research Square
PDF
Signature immunologique de la gonarthrose : rôle des lymphocytes T régulateurs dans la douleur. Résultats de l’étude TRANSIMMUNOM
2024 · M. Binvignat, J. Dubois, et al. · Revue du Rhumatisme
Pos0792 Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis
2024 · M. Binvignat, J. Dubois, et al. · Annals of the Rheumatic Diseases
Immunological Profiling of Pain in Knee Osteoarthritis: Treg Cells as Potential New Key Players in Symptomatic Knee Osteoarthritis.
2024 · Marie Binvignat, Johanna Dubois, et al. · Osteoarthritis and Cartilage
PDF
Works count: 17
Citation count: 579
H-index: 7
I10-index: 6
Year
Topic
Type